P3+ Intervention Phase
4 de agosto de 2020 actualizado por: Robert Bednarczyk, Emory University
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
This study will address vaccine uptake both for pregnant women and for their children, through 20 months of age, to test the hypothesis that exposure to the P3+ intervention package will increase the likelihood a pregnant woman gets herself vaccinated against influenza and pertussis before delivery and get her child vaccinated on time.
This study builds off of a prior intervention, developed by Emory, at the practice, provider, and patient levels (P3) to develop, implement and evaluate an enhanced intervention (P3+) to improve vaccination uptake among pregnant women, and later, their children.
Descripción general del estudio
Estado
Terminado
Condiciones
Descripción detallada
This study will address vaccine uptake both for pregnant women and for their children, through 20 months of age, to test the hypothesis that exposure to the P3+ intervention package will increase the likelihood a pregnant woman gets herself vaccinated against influenza and pertussis before delivery and get her child vaccinated on time.
This study uses a multi-level factorial design which randomizes at both the practice and the patient level. Obstetric practices in Georgia and Colorado will be randomized to be either an intervention practice or a control practice. The women recruited in the practices and enrolled in the study will be randomly assigned to the intervention arm or the control arm.
Women randomized to the intervention arm will complete a computer-based questionnaire (administered via iPad with a preloaded study app) which asks for their basic demographic and contact information and asks questions about their vaccine knowledge, attitudes, and beliefs. Immediately following the questionnaire, participants will receive the individual level intervention (videos providing information on vaccines) on the same iPad. In order to best answer their questions and not provide information beyond the scope of what the study participants need or want, the videos provided to each participant will be selected based on responses to the survey questions. There are 6 videos: one discusses the dangers of the diseases prevented by vaccines, and the others address specific vaccine concerns (concerns include vaccine ingredients, children receiving simultaneous vaccines (multiple vaccines at one time), and the safety of receiving the tdap or flu vaccine during pregnancy). If the participant does not have any concerns, they will only see the video about dangers of vaccine preventable diseases. Participants expressing concerns in the survey will receive up to two videos addressing those concerns, based on an order of priority determined by the study researchers.
Women randomized to the control arm will also complete a computer-based questionnaire which includes their personal information and vaccine knowledge, attitudes, and beliefs questions but will then continue to receive usual prenatal care rather than view informational videos.
All enrolled women complete two follow-up surveys when their children are 30 days and 18 months of age.
Tipo de estudio
Intervencionista
Inscripción (Actual)
2200
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- CU Center for Midwifery
-
Aurora, Colorado, Estados Unidos, 80045
- CU Maternal and Fetal Medicine Clinic
-
Aurora, Colorado, Estados Unidos, 80045
- University Nurse Midwives
-
Boulder, Colorado, Estados Unidos, 80303
- Boulder Women's Care
-
Denver, Colorado, Estados Unidos, 80218
- St. Joe's Midwives
-
Denver, Colorado, Estados Unidos, 80220
- Partners in Women's Health at Rose
-
Denver, Colorado, Estados Unidos, 80220
- Rocky Mountain OBGYN
-
Edwards, Colorado, Estados Unidos, 81632
- Colorado Mountain Medical
-
Englewood, Colorado, Estados Unidos, 80113
- Bella Natural Women's Care
-
Golden, Colorado, Estados Unidos, 80401
- Associates in Women's Health
-
Thornton, Colorado, Estados Unidos, 80229
- Women's Health Group Thornton
-
-
Georgia
-
Alpharetta, Georgia, Estados Unidos, 30005
- Atlanta Women's Specialists
-
Alpharetta, Georgia, Estados Unidos, 30005
- Roswell Ob/Gyn
-
Athens, Georgia, Estados Unidos, 30606
- Athens Midwifery
-
Athens, Georgia, Estados Unidos, 30606
- Athens Ob-Gyn
-
Athens, Georgia, Estados Unidos, 30606
- Women's Healthcare Associates of Athens
-
Atlanta, Georgia, Estados Unidos, 30322
- Emory Clinic
-
Atlanta, Georgia, Estados Unidos, 30342
- Riverbend OB/GYN and Counseling
-
Cumming, Georgia, Estados Unidos, 30041
- Peachtree Women's Clinic
-
Duluth, Georgia, Estados Unidos, 30096
- Comprehensive Women's OB/GYN
-
Dunwoody, Georgia, Estados Unidos, 30338
- Dunwoody Ob-Gyn
-
Lilburn, Georgia, Estados Unidos, 30047
- Atlanta Gynecology & Obstetrics
-
Tyrone, Georgia, Estados Unidos, 30290
- Women's Medical Center
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años a 50 años (Adulto)
Acepta Voluntarios Saludables
Sí
Géneros elegibles para el estudio
Femenino
Descripción
Inclusion Criteria:
- Have not previously participated in this study
- Currently pregnant
- Up to 26 weeks gestational age
- Able to understand and communicate in English
Exclusion Criteria:
- Have received pertussis vaccine during the current pregnancy
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Investigación de servicios de salud
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación factorial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Otro: Control Site + Control Patient
The obstetric practice site is randomized to be a control site and the patient is randomized to the control group.
|
Control sites will continue with their standard practice regarding discussing vaccines with their patients.
Otros nombres:
Participants randomized the control arm will complete a computer-based questionnaire, on an iPad with a preloaded app.
The questionnaire asks about vaccine knowledge, attitudes, and beliefs and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby.
The questionnaire includes questions requiring a "yes" or "no" response, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), questions to capture the vaccines participants plan to get for themselves and their children, and open-ended questions.
|
|
Experimental: Control Site + Intervention Patient
The obstetric practice site is randomized to be a control site and the patient is randomized to receive the intervention.
|
Control sites will continue with their standard practice regarding discussing vaccines with their patients.
Otros nombres:
Participants randomized to the intervention arm will complete a computer-based questionnaire on an iPad with a preloaded app, prior to watching informational videos covering topics on maternal and childhood vaccines.
The questionnaire asks about vaccine knowledge, attitudes, beliefs, and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby.
The questions require "yes" or "no" responses, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), and open-ended responses.
After watching at least one informational video, the participant completes a questionnaire asking about the perceived usefulness of the app, degree of agreement with the vaccine information presented in the video, and ways to make the app more useful to participants.
|
|
Experimental: Intervention Site + Control Patient
The obstetric practice site is randomized to be an intervention site and the patient is randomized to the control group.
|
Participants randomized the control arm will complete a computer-based questionnaire, on an iPad with a preloaded app.
The questionnaire asks about vaccine knowledge, attitudes, and beliefs and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby.
The questionnaire includes questions requiring a "yes" or "no" response, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), questions to capture the vaccines participants plan to get for themselves and their children, and open-ended questions.
Intervention Sites will each assign a Vaccine Champion and will have Assessment, Feedback, Incentives, and eXchange (AFIX) visits.
AFIX is a quality improvement program to raise immunization coverage levels, reduce missed opportunities to vaccinate, and improve standards of practices at the provider level.
A Continuing Medical Education (CME) module will be given to all providers, covering the recommended maternal vaccinations and how to talk to patients about vaccines.
Intervention sites will have access to written materials covering all recommended maternal and infant vaccinations, the diseases they prevent, potential adverse reactions and common patient questions with talking points and references for each topic.
Otros nombres:
|
|
Experimental: Intervention Site + Intervention Patient
The obstetric practice site is randomized to be an intervention site and the patient is randomized to receive the intervention.
|
Participants randomized to the intervention arm will complete a computer-based questionnaire on an iPad with a preloaded app, prior to watching informational videos covering topics on maternal and childhood vaccines.
The questionnaire asks about vaccine knowledge, attitudes, beliefs, and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby.
The questions require "yes" or "no" responses, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), and open-ended responses.
After watching at least one informational video, the participant completes a questionnaire asking about the perceived usefulness of the app, degree of agreement with the vaccine information presented in the video, and ways to make the app more useful to participants.
Intervention Sites will each assign a Vaccine Champion and will have Assessment, Feedback, Incentives, and eXchange (AFIX) visits.
AFIX is a quality improvement program to raise immunization coverage levels, reduce missed opportunities to vaccinate, and improve standards of practices at the provider level.
A Continuing Medical Education (CME) module will be given to all providers, covering the recommended maternal vaccinations and how to talk to patients about vaccines.
Intervention sites will have access to written materials covering all recommended maternal and infant vaccinations, the diseases they prevent, potential adverse reactions and common patient questions with talking points and references for each topic.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of women receiving influenza vaccination
Periodo de tiempo: Up to 34 weeks
|
Whether or not the participant chose to receive the flu vaccine during pregnancy (between the baseline visit and birth of infant) will be compared between study arms
|
Up to 34 weeks
|
|
Number of women receiving pertussis vaccination
Periodo de tiempo: Up to 34 weeks
|
Whether or not the participant chose to receive the pertussis vaccine during pregnancy (between the baseline visit and birth of infant) will be compared between study arms
|
Up to 34 weeks
|
|
Timely childhood vaccinations
Periodo de tiempo: 20 months
|
Childhood vaccination will be assessed as timely uptake of childhood vaccines by calculating average days under-vaccinated.
The total number of days under-vaccinated will be divided by the number of vaccines a child should have received, according to the Advisory Committee on Immunization Practices (ACIP) schedule, to give the average number of days under-vaccinated across all recommended vaccines.
This can range from 0 to 415 days in the first 20 months of life.
The average number of days under-vaccinated will be modeled as a continuous variable, and the distribution of days under-vaccinated will be evaluated, in total and by vaccine where possible, to identify specific patterns of interest for follow-up.
|
20 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Changes in maternal vaccine knowledge
Periodo de tiempo: Up to 106 weeks (baseline visit until 18 months post delivery)
|
Maternal vaccine knowledge will be collected by the app surveys at different time periods, including before receiving the patient-level intervention, immediately after receiving the intervention, and 30 days and 18 months after the birth of the child.
The survey questions assessing these outcomes will most often be measured on a Likert scale.
Changes in these outcomes over time will be compared between mothers in the different study arms.
|
Up to 106 weeks (baseline visit until 18 months post delivery)
|
|
Changes in maternal vaccine attitudes
Periodo de tiempo: Up to 106 weeks (baseline visit until 18 months post delivery)
|
Maternal vaccine attitudes will be collected by the app surveys at different time periods, including before receiving the patient-level intervention, immediately after receiving the intervention, and 30 days and 18 months after the birth of the child.
The survey questions assessing these outcomes will most often be measured on a Likert scale.
Changes in these outcomes over time will be compared between mothers in the different study arms.
|
Up to 106 weeks (baseline visit until 18 months post delivery)
|
|
Changes in maternal vaccine beliefs
Periodo de tiempo: Up to 106 weeks (baseline visit until 18 months post delivery)
|
Maternal vaccine beliefs will be collected by the app surveys at different time periods, including before receiving the patient-level intervention, immediately after receiving the intervention, and 30 days and 18 months after the birth of the child.
The survey questions assessing these outcomes will most often be measured on a Likert scale.
Changes in these outcomes over time will be compared between mothers in the different study arms.
|
Up to 106 weeks (baseline visit until 18 months post delivery)
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Investigador principal: Daniel Salmon, PhD, MPH, Johns Hopkins Bloomberg School of Public Health
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
12 de junio de 2017
Finalización primaria (Actual)
6 de julio de 2020
Finalización del estudio (Actual)
6 de julio de 2020
Fechas de registro del estudio
Enviado por primera vez
8 de septiembre de 2016
Primero enviado que cumplió con los criterios de control de calidad
8 de septiembre de 2016
Publicado por primera vez (Estimar)
13 de septiembre de 2016
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
5 de agosto de 2020
Última actualización enviada que cumplió con los criterios de control de calidad
4 de agosto de 2020
Última verificación
1 de agosto de 2020
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- IRB00090267
- 5R01AI110482-02 (Subvención/contrato del NIH de EE. UU.)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .